Bravelle

Bravelle (Urofollitropin) is a human derived gonadotropin purified from extracted urine of postmenopausal women. It is indicated for the development of multiple follicles during ovulation for patients having assistance in reproduction. It is given with hCG to to cause ovulation in patients unable to ovulate with functional infertility.

Size Price Qty Add
1 box containing 5 (75-unit) vials
RRP: $684.76
You pay: $589.95 (Save 14%)

General Product Information About Bravelle

Bravelle Product Contains

Urofollitropin

Bravelle Product Indications

Bravelle (urofollitropin) is a human-derived gonadotropin purified from extracted urine of postmenopausal women. It is indicated for ovulation induction and for the development of multiple follicles during ovulation for patients participating in an Assisted Reproductive Technology (ART) program. Patients must be given hCG to induce ovulation following treatment with Bravelle.

Bravelle Dosage and Administration

NOTE: During FSH treatment and for 2 weeks after treatment, patients need to be checked every day (or every other day) for signs of too much ovarian stimulation.

Induction of ovulation and pregnancy in patients who do not ovulate when infertility is not due to ovarian failure

  • Initial dose 150 IU subcutaneously or intramuscularly once daily for the first 5 days of treatment for patients who receive GnRH agonist or antagonist pituitary suppression and then adjust the dose based upon response. No more than 75-150 IU daily for every 2 days. Maximum dose 450 IU/day
  • hCG should be given once sufficient response is shown unless the serum estradiol is greater than 2000 pg/mL.
  • Course may be repeated if adequate ovulation does not occur.

For the development for multiple follicles in patient¿s participating in assisted reproductive programs

  • Initial dose 225 IU subcutaneously for at least the first 5 days for patients who receive GnRH agonist or antagonist pituitary suppression and then adjust the dose based upon response. No more than 75-150 IU daily for every 2 days. Maximum dose 450 IU/day
  • hCG should be administered to retrieve oocyte.
  • Do not exceed 12 days of therapy
  • Course may be repeated if adequate ovulation does not occur.

Bravelle Warnings, Side Effects and Potential Drug Interactions

  • Discontinue treatment if the ovaries become abnormally enlarged or if abdominal pain occurs and contact your physician
  • Do not use if pregnant or breastfeeding
  • Sexual intercourse is prohibited if ovaries are enlarged
  • Some side effects include: acne, breast tenderness, mood changes, hot flashes, vaginal bleeding
  • May enhance some cancers such as ovarian or breast cancer

Bravelle Storage

  • Store in refrigerator or at room temperature, between 36°-77° F (2°-25° C)
  • Use immediately after reconstitution
  • Avoid excessive heat, humidity, and light.

Bravelle Manufacturer

Ferring Pharmaceuticals, Inc
Website : www.ferring.com

Approved by the FDA
Federal law restricts/prohibits dispensing without prescription.

Style Number: FER-RFO-00001-CONFIG